---
pmid: '24212136'
title: Chemical inhibition of prometastatic lysyl-tRNA synthetase-laminin receptor
  interaction.
authors:
- Kim DG
- Lee JY
- Kwon NH
- Fang P
- Zhang Q
- Wang J
- Young NL
- Guo M
- Cho HY
- Mushtaq AU
- Jeon YH
- Choi JW
- Han JM
- Kang HW
- Joo JE
- Hur Y
- Kang W
- Yang H
- Nam DH
- Lee MS
- Lee JW
- Kim ES
- Moon A
- Kim K
- Kim D
- Kang EJ
- Moon Y
- Rhee KH
- Han BW
- Yang JS
- Han G
- Yang WS
- Lee C
- Wang MW
- Kim S
journal: Nat Chem Biol
year: '2014'
full_text_available: false
pmcid: PMC4021855
doi: 10.1038/nchembio.1381
---

# Chemical inhibition of prometastatic lysyl-tRNA synthetase-laminin receptor interaction.
**Authors:** Kim DG, Lee JY, Kwon NH, Fang P, Zhang Q, Wang J, Young NL, Guo M, Cho HY, Mushtaq AU, Jeon YH, Choi JW, Han JM, Kang HW, Joo JE, Hur Y, Kang W, Yang H, Nam DH, Lee MS, Lee JW, Kim ES, Moon A, Kim K, Kim D, Kang EJ, Moon Y, Rhee KH, Han BW, Yang JS, Han G, Yang WS, Lee C, Wang MW, Kim S
**Journal:** Nat Chem Biol (2014)
**DOI:** [10.1038/nchembio.1381](https://doi.org/10.1038/nchembio.1381)
**PMC:** [PMC4021855](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021855/)

## Abstract

1. Nat Chem Biol. 2014 Jan;10(1):29-34. doi: 10.1038/nchembio.1381. Epub 2013 Nov
 10.

Chemical inhibition of prometastatic lysyl-tRNA synthetase-laminin receptor 
interaction.

Kim DG(1), Lee JY(1), Kwon NH(2), Fang P(3), Zhang Q(4), Wang J(3), Young NL(5), 
Guo M(3), Cho HY(6), Mushtaq AU(6), Jeon YH(6), Choi JW(7), Han JM(2), Kang 
HW(8), Joo JE(8), Hur Y(8), Kang W(9), Yang H(9), Nam DH(9), Lee MS(10), Lee 
JW(10), Kim ES(11), Moon A(11), Kim K(2), Kim D(2), Kang EJ(12), Moon Y(12), 
Rhee KH(10), Han BW(10), Yang JS(13), Han G(13), Yang WS(2), Lee C(14), Wang 
MW(15), Kim S(16).

Author information:
(1)1] Medicinal Bioconvergence Research Center, Seoul National University, 
Seoul, Korea. [2] Research Institute of Pharmaceutical Sciences, College of 
Pharmacy, Seoul National University, Seoul, Korea. [3].
(2)1] Medicinal Bioconvergence Research Center, Seoul National University, 
Seoul, Korea. [2] Research Institute of Pharmaceutical Sciences, College of 
Pharmacy, Seoul National University, Seoul, Korea.
(3)Department of Cancer Biology, The Scripps Research Institute, Scripps 
Florida, Jupiter, Florida, USA.
(4)Department of Chemistry and Biochemistry, Florida State University, 
Tallahassee, Florida, USA.
(5)Ion Cyclotron Resonance Program, National High Magnetic Field Laboratory, 
Florida State University, Tallahassee, Florida, USA.
(6)College of Pharmacy, Korea University, Sejong, Korea.
(7)1] Medicinal Bioconvergence Research Center, Seoul National University, 
Seoul, Korea. [2] Wellman Center for Photomedicine, Massachusetts General 
Hospital, Harvard Medical School, Boston, Massachusetts, USA.
(8)Yuhan Research Institute, Yongin, Korea.
(9)Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University 
School of Medicine, Seoul, Korea.
(10)Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul 
National University, Seoul, Korea.
(11)College of Pharmacy, Duksung Women's University, Seoul, Korea.
(12)Medicinal Bioconvergence Research Center, Seoul National University, Seoul, 
Korea.
(13)Translational Research Center for Protein Function Control, Department of 
Biotechnology and WCU Department of Biomedical Sciences, Yonsei University, 
Seoul, Korea.
(14)BRI, Korea Institute of Science and Technology, Seoul, Korea.
(15)The National Center for Drug Screening, Zhangjiang High-Tech Park, Shanghai, 
China.
(16)1] Medicinal Bioconvergence Research Center, Seoul National University, 
Seoul, Korea. [2] Research Institute of Pharmaceutical Sciences, College of 
Pharmacy, Seoul National University, Seoul, Korea. [3] World Class University 
Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National 
University, Seoul, Korea.

Lysyl-tRNA synthetase (KRS), a protein synthesis enzyme in the cytosol, 
relocates to the plasma membrane after a laminin signal and stabilizes a 67-kDa 
laminin receptor (67LR) that is implicated in cancer metastasis; however, its 
potential as an antimetastatic therapeutic target has not been explored. We 
found that the small compound BC-K-YH16899, which binds KRS, impinged on the 
interaction of KRS with 67LR and suppressed metastasis in three different mouse 
models. The compound inhibited the KRS-67LR interaction in two ways. First, it 
directly blocked the association between KRS and 67LR. Second, it suppressed the 
dynamic movement of the N-terminal extension of KRS and reduced membrane 
localization of KRS. However, it did not affect the catalytic activity of KRS. 
Our results suggest that specific modulation of a cancer-related KRS-67LR 
interaction may offer a way to control metastasis while avoiding the toxicities 
associated with inhibition of the normal functions of KRS.

DOI: 10.1038/nchembio.1381
PMCID: PMC4021855
PMID: 24212136 [Indexed for MEDLINE]

Conflict of interest statement: Competing financial interests The authors 
declare no competing financial interests.
